TopicalDosed ingredient Cosmetic cross-reference

Oxybenzone

CAS 131-57-7

Oxybenzone (CAS 131-57-7) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 51 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Oxybenzone

CAS Number

131-57-7

UNII

95OOS7VE0Y

InChIKey

DXGLGDHPHMLXJC-UHFFFAOYSA-N

ChEMBL ID

CHEMBL1625

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

dosed ingredientnatural producttopical

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL1625 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 5 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	27452.162676056338 nM	71	-
-	Potency	28780.533333333333 nM	32	-
-	IC50	14400.873333333331 nM	2	-
-	IC50	4.9 ug.mL-1	1	-
Hormone-sensitive lipase Enzyme	IC50	5.49	-	Rattus norvegicus

SOURCE DrugCentral 51 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Macular degeneration	263	958.026	10025409
Therapy interrupted	143	375.555	10066377
Chronic sinusitis	93	294.886	10009137
Death	344	269.392	10011906
Paraesthesia oral	93	259.097	10057372
Procedural pain	93	250.094	10064882
Therapy cessation	100	221.653	10065154
Vaginal flatulence	39	149.024	10064227
Female genital tract fistula	41	127.13	10061149
Therapeutic product effect incomplete	114	123.127	10082200
Surgery	68	122.341	10042609
Dyspepsia	99	117.83	10013946
Vaginal discharge	39	111.756	10046901
Proctitis	38	111.244	10036774
Radiculopathy	39	103.29	10037779
Squamous cell carcinoma of skin	43	102.859	10041834
Hospitalisation	87	92.605	10054112
Drug ineffective	322	88.254	10013709
Anal inflammation	21	82.914	10050247
Colitis ulcerative	46	71.212	10009900
SARS-CoV-2 test negative	18	70.043	10084273
Frequent bowel movements	41	65.732	10017367
Oral candidiasis	39	62.597	10030963
Pyrexia	186	62.368	10037660
Skin atrophy	23	59.536	10040799
Infusion related reaction	100	50.574	10051792
Weight decreased	121	50.193	10047895
Rectal haemorrhage	50	49.847	10038063
Accident	22	46.607	10000369
Proctalgia	22	45.078	10036772
Malaise	137	44.042	10025482
Neoplasm skin	14	43.263	10029098
Ochronosis	7	42.946	10051253
Colitis	43	38.182	10009887
Constipation	94	38.049	10010774
Appendicolith	17	36.194	10074458
Haematochezia	45	36.133	10018836
Pain	175	35.121	10033371
Intentional dose omission	18	33.332	10079221
Drug intolerance	3	24.962	10061822
Spinal operation	14	24.186	10062262
Nausea	184	22.473	10028813
Haemorrhoids	22	22.291	10019022
Drug interaction	7	22.15	10013710
Appendicitis	17	20.458	10003011
Ventricular fibrillation	20	20.16	10047290
Language disorder	9	19.242	10074869
Transferrin saturation abnormal	4	18.554	10079855
Anal injury	4	18.183	10055023
Joint swelling	7	17.951	10023232

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

Name	RxCUI	Type	Source
OXYBENZONE	32673	SU	MTHSPL
oxybenzone	32673	IN	RXNORM

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Oxybenzone used for in pharmaceutical contexts?

Oxybenzone (CAS 131-57-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Oxybenzone?

Oxybenzone has 51 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Macular degeneration, Therapy interrupted, Chronic sinusitis, Death, Paraesthesia oral. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Oxybenzone also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Benzophenone-3 (Oxybenzone) with EU status "restricted".

What clinical phase is Oxybenzone in?

Oxybenzone is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Oxybenzone?

Oxybenzone has 5 bioactivity rows in this page query. Rendered target entries include Hormone-sensitive lipase.